Including 38 wikipathways in ASD, 22 in ID, 20 in EE and 39 in SCZ. |
wiki accession | wiki pathway name | Number of reference genes | Number of genes | Expected number | Ratio of entrichment | Raw P_Value | Adjusted P_Value | Genes related | Other disease |
---|---|---|---|---|---|---|---|---|---|
DB_ID:141 | Unblocking of NMDA receptor, glutamate binding and activation | 11 | 4 | 0.03 | 147.95 | 1.12e-08 | 1.76e-06 | - | |
DB_ID:143 | Neuronal System | 188 | 8 | 0.46 | 17.31 | 2.35e-08 | 1.84e-06 | EE ASD SCZ | |
DB_ID:197 | CREB phosphorylation through the activation of CaMKII | 15 | 4 | 0.04 | 108.50 | 4.61e-08 | 2.41e-06 | - | |
DB_ID:167 | Ras activation uopn Ca2+ infux through NMDA receptor | 17 | 4 | 0.04 | 95.73 | 8.00e-08 | 3.14e-06 | - | |
DB_ID:1573 | ErbB receptor signaling network | 1312 | 15 | 3.22 | 4.65 | 7.95e-07 | 1.56e-05 | ASD SCZ | |
DB_ID:150 | Transmission across Chemical Synapses | 121 | 6 | 0.30 | 20.17 | 5.84e-07 | 1.56e-05 | EE ASD SCZ | |
DB_ID:1662 | TGFBR | 125 | 6 | 0.31 | 19.53 | 7.07e-07 | 1.56e-05 | SCZ | |
DB_ID:166 | CREB phosphorylation through the activation of Ras | 28 | 4 | 0.07 | 58.12 | 6.74e-07 | 1.56e-05 | ASD | |
DB_ID:140 | Activation of NMDA receptor upon glutamate binding and postsynaptic events | 34 | 4 | 0.08 | 47.87 | 1.51e-06 | 2.37e-05 | ASD SCZ | |
DB_ID:142 | Post NMDA receptor activation events | 34 | 4 | 0.08 | 47.87 | 1.51e-06 | 2.37e-05 | ASD SCZ | |
DB_ID:1037 | Apoptotic cleavage of cell adhesion proteins | 12 | 3 | 0.03 | 101.71 | 3.12e-06 | 4.45e-05 | - | |
DB_ID:1480 | TRAIL signaling pathway | 1328 | 14 | 3.26 | 4.29 | 4.86e-06 | 6.36e-05 | ASD SCZ | |
DB_ID:1564 | IL3-mediated signaling events | 1295 | 13 | 3.18 | 4.08 | 1.82e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1575 | VEGF and VEGFR signaling network | 1304 | 13 | 3.21 | 4.06 | 1.96e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1619 | Endothelins | 1307 | 13 | 3.21 | 4.05 | 2.01e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1603 | EGFR-dependent Endothelin signaling events | 1289 | 13 | 3.17 | 4.10 | 1.74e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1553 | Class I PI3K signaling events | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1497 | PDGF receptor signaling network | 1293 | 13 | 3.18 | 4.09 | 1.79e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1578 | Alpha9 beta1 integrin signaling events | 1305 | 13 | 3.21 | 4.05 | 1.97e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1519 | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1491 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | 1293 | 13 | 3.18 | 4.09 | 1.79e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1540 | PDGFR-beta signaling pathway | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1649 | LKB1 signaling events | 1308 | 13 | 3.21 | 4.04 | 2.02e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1516 | Signaling events mediated by VEGFR1 and VEGFR2 | 1296 | 13 | 3.19 | 4.08 | 1.84e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1602 | ErbB1 downstream signaling | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1482 | IGF1 pathway | 1291 | 13 | 3.17 | 4.10 | 1.76e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1556 | Plasma membrane estrogen receptor signaling | 1301 | 13 | 3.20 | 4.07 | 1.91e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1552 | Thrombin/protease-activated receptor (PAR) pathway | 1300 | 13 | 3.20 | 4.07 | 1.90e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1615 | Arf6 trafficking events | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1509 | Internalization of ErbB1 | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1550 | EGF receptor (ErbB1) signaling pathway | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1472 | Nectin adhesion pathway | 1295 | 13 | 3.18 | 4.08 | 1.82e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1529 | IFN-gamma pathway | 1296 | 13 | 3.19 | 4.08 | 1.84e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1571 | mTOR signaling pathway | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1585 | Arf6 downstream pathway | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1454 | Syndecan-1-mediated signaling events | 1300 | 13 | 3.20 | 4.07 | 1.90e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1648 | Class I PI3K signaling events mediated by Akt | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1466 | Insulin Pathway | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1554 | Arf6 signaling events | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:389 | Cell Cycle, Mitotic | 318 | 7 | 0.78 | 8.96 | 1.45e-05 | 6.89e-05 | - | |
DB_ID:1492 | Glypican 1 network | 1299 | 13 | 3.19 | 4.07 | 1.88e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1531 | PAR1-mediated thrombin signaling events | 1299 | 13 | 3.19 | 4.07 | 1.88e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1461 | GMCSF-mediated signaling events | 1292 | 13 | 3.18 | 4.09 | 1.78e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1627 | IL5-mediated signaling events | 1292 | 13 | 3.18 | 4.09 | 1.78e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1574 | Signaling events mediated by focal adhesion kinase | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1594 | S1P1 pathway | 1288 | 13 | 3.17 | 4.11 | 1.72e-05 | 6.89e-05 | ASD SCZ | |
DB_ID:1635 | Sphingosine 1-phosphate (S1P) pathway | 1311 | 13 | 3.22 | 4.03 | 2.07e-05 | 6.91e-05 | ASD SCZ | |
DB_ID:1459 | Glypican pathway | 1338 | 13 | 3.29 | 3.95 | 2.56e-05 | 8.37e-05 | ASD SCZ | |
DB_ID:1637 | Proteoglycan syndecan-mediated signaling events | 1345 | 13 | 3.31 | 3.93 | 2.70e-05 | 8.65e-05 | ASD SCZ | |
DB_ID:1517 | Beta1 integrin cell surface interactions | 1351 | 13 | 3.32 | 3.91 | 2.83e-05 | 8.89e-05 | ASD SCZ | |
DB_ID:1499 | Integrin family cell surface interactions | 1378 | 13 | 3.39 | 3.84 | 3.47e-05 | 0.0001 | ASD SCZ | |
DB_ID:99 | DNA Replication | 261 | 6 | 0.64 | 9.35 | 4.77e-05 | 0.0001 | - | |
DB_ID:1523 | Reelin signaling pathway | 29 | 3 | 0.07 | 42.09 | 5.03e-05 | 0.0001 | ASD SCZ | |
DB_ID:130 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | 89 | 4 | 0.22 | 18.29 | 7.17e-05 | 0.0002 | EE ASD SCZ | |
DB_ID:1657 | Wnt | 82 | 4 | 0.20 | 19.85 | 5.20e-05 | 0.0002 | SCZ | |
DB_ID:1035 | Apoptotic cleavage of cellular proteins | 39 | 3 | 0.10 | 31.30 | 0.0001 | 0.0003 | - | |
DB_ID:1040 | Apoptotic execution phase | 48 | 3 | 0.12 | 25.43 | 0.0002 | 0.0006 | - | |
DB_ID:96 | Mitotic M-M/G1 phases | 242 | 5 | 0.59 | 8.41 | 0.0003 | 0.0008 | - | |
DB_ID:1494 | N-cadherin signaling events | 251 | 5 | 0.62 | 8.10 | 0.0004 | 0.0011 | ASD SCZ | |
DB_ID:1506 | Coregulation of Androgen receptor activity | 61 | 3 | 0.15 | 20.01 | 0.0005 | 0.0013 | - | |
DB_ID:1544 | E-cadherin signaling in the nascent adherens junction | 275 | 5 | 0.68 | 7.40 | 0.0006 | 0.0015 | ASD SCZ | |
DB_ID:1068 | Apoptosis | 158 | 4 | 0.39 | 10.30 | 0.0006 | 0.0015 | - | |
DB_ID:1469 | Stabilization and expansion of the E-cadherin adherens junction | 275 | 5 | 0.68 | 7.40 | 0.0006 | 0.0015 | ASD SCZ | |
DB_ID:97 | M Phase | 158 | 4 | 0.39 | 10.30 | 0.0006 | 0.0015 | - | |
DB_ID:11 | Developmental Biology | 433 | 6 | 1.06 | 5.64 | 0.0007 | 0.0017 | ASD SCZ | |
DB_ID:1617 | E-cadherin signaling events | 280 | 5 | 0.69 | 7.27 | 0.0007 | 0.0017 | ASD SCZ | |
DB_ID:164 | GABA synthesis, release, reuptake and degradation | 17 | 2 | 0.04 | 47.87 | 0.0008 | 0.0019 | ASD | |
DB_ID:1546 | Integrin-linked kinase signaling | 656 | 7 | 1.61 | 4.34 | 0.0012 | 0.0027 | ASD SCZ | |
DB_ID:137 | Trafficking of AMPA receptors | 21 | 2 | 0.05 | 38.75 | 0.0012 | 0.0027 | - | |
DB_ID:136 | Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity | 21 | 2 | 0.05 | 38.75 | 0.0012 | 0.0027 | - | |
DB_ID:91 | Mitotic Metaphase/Anaphase Transition | 22 | 2 | 0.05 | 36.99 | 0.0013 | 0.0029 | - | |
DB_ID:1572 | RAC1 signaling pathway | 205 | 4 | 0.50 | 7.94 | 0.0017 | 0.0036 | ASD | |
DB_ID:1530 | Regulation of RAC1 activity | 205 | 4 | 0.50 | 7.94 | 0.0017 | 0.0036 | ASD | |
DB_ID:1650 | Regulation of RhoA activity | 205 | 4 | 0.50 | 7.94 | 0.0017 | 0.0036 | ASD | |
DB_ID:1647 | RhoA signaling pathway | 205 | 4 | 0.50 | 7.94 | 0.0017 | 0.0036 | ASD | |
DB_ID:157 | Neurotransmitter Release Cycle | 26 | 2 | 0.06 | 31.30 | 0.0019 | 0.0039 | ASD | |
DB_ID:20 | Axon guidance | 219 | 4 | 0.54 | 7.43 | 0.0021 | 0.0043 | ASD SCZ | |
DB_ID:1636 | Regulation of Androgen receptor activity | 108 | 3 | 0.27 | 11.30 | 0.0024 | 0.0048 | SCZ | |
DB_ID:384 | G1 Phase | 31 | 2 | 0.08 | 26.25 | 0.0027 | 0.0052 | - | |
DB_ID:1488 | CDC42 signaling events | 757 | 7 | 1.86 | 3.76 | 0.0027 | 0.0052 | ASD SCZ | |
DB_ID:394 | Cyclin D associated events in G1 | 31 | 2 | 0.08 | 26.25 | 0.0027 | 0.0052 | - | |
DB_ID:1512 | Posttranslational regulation of adherens junction stability and dissassembly | 231 | 4 | 0.57 | 7.05 | 0.0026 | 0.0052 | ASD SCZ | |
DB_ID:1584 | ErbB4 signaling events | 32 | 2 | 0.08 | 25.43 | 0.0028 | 0.0053 | - | |
DB_ID:1456 | Regulation of CDC42 activity | 770 | 7 | 1.89 | 3.70 | 0.0030 | 0.0056 | ASD SCZ | |
DB_ID:1618 | Androgen-mediated signaling | 130 | 3 | 0.32 | 9.39 | 0.0041 | 0.0075 | SCZ | |
DB_ID:1559 | FAS (CD95) signaling pathway | 130 | 3 | 0.32 | 9.39 | 0.0041 | 0.0075 | ASD | |
DB_ID:171 | Voltage gated Potassium channels | 39 | 2 | 0.10 | 20.86 | 0.0042 | 0.0076 | EE ASD | |
DB_ID:1565 | AP-1 transcription factor network | 623 | 6 | 1.53 | 3.92 | 0.0045 | 0.0080 | ASD SCZ | |
DB_ID:1547 | Regulation of nuclear beta catenin signaling and target gene transcription | 135 | 3 | 0.33 | 9.04 | 0.0046 | 0.0081 | ASD SCZ | |
DB_ID:388 | Mitotic G1-G1/S phases | 141 | 3 | 0.35 | 8.66 | 0.0052 | 0.0091 | - | |
DB_ID:756 | Meiotic Synapsis | 47 | 2 | 0.12 | 17.31 | 0.0060 | 0.0104 | SCZ | |
DB_ID:1522 | Ceramide signaling pathway | 49 | 2 | 0.12 | 16.61 | 0.0065 | 0.0110 | - | |
DB_ID:1557 | FoxO family signaling | 49 | 2 | 0.12 | 16.61 | 0.0065 | 0.0110 | EE | |
DB_ID:1542 | Canonical Wnt signaling pathway | 155 | 3 | 0.38 | 7.87 | 0.0067 | 0.0112 | ASD SCZ | |
DB_ID:1501 | Caspase cascade in apoptosis | 52 | 2 | 0.13 | 15.65 | 0.0073 | 0.0121 | ASD | |
DB_ID:351 | Loss of Nlp from mitotic centrosomes | 61 | 2 | 0.15 | 13.34 | 0.0100 | 0.0162 | - | |
DB_ID:354 | Loss of proteins required for interphase microtubule organization from the centrosome | 61 | 2 | 0.15 | 13.34 | 0.0100 | 0.0162 | - | |
DB_ID:1535 | Noncanonical Wnt signaling pathway | 182 | 3 | 0.45 | 6.71 | 0.0104 | 0.0163 | ASD SCZ | |
DB_ID:94 | Mitotic Prophase | 62 | 2 | 0.15 | 13.12 | 0.0103 | 0.0163 | - | |
DB_ID:95 | Golgi Cisternae Pericentriolar Stack Reorganization | 62 | 2 | 0.15 | 13.12 | 0.0103 | 0.0163 | - | |
DB_ID:1623 | Regulation of retinoblastoma protein | 66 | 2 | 0.16 | 12.33 | 0.0116 | 0.0180 | ASD | |
DB_ID:1513 | BCR signaling pathway | 67 | 2 | 0.16 | 12.15 | 0.0119 | 0.0183 | - | |
DB_ID:372 | Centrosome maturation | 70 | 2 | 0.17 | 11.62 | 0.0130 | 0.0196 | - | |
DB_ID:371 | Recruitment of mitotic centrosome proteins and complexes | 70 | 2 | 0.17 | 11.62 | 0.0130 | 0.0196 | - | |
DB_ID:1435 | Wnt signaling network | 200 | 3 | 0.49 | 6.10 | 0.0134 | 0.0200 | ASD SCZ | |
DB_ID:758 | Meiosis | 72 | 2 | 0.18 | 11.30 | 0.0137 | 0.0203 | SCZ | |
DB_ID:1626 | E2F transcription factor network | 73 | 2 | 0.18 | 11.15 | 0.0140 | 0.0205 | - | |
DB_ID:527 | Signaling by Wnt | 75 | 2 | 0.18 | 10.85 | 0.0148 | 0.0211 | - | |
DB_ID:528 | Degradation of beta-catenin by the destruction complex | 75 | 2 | 0.18 | 10.85 | 0.0148 | 0.0211 | - | |
DB_ID:1471 | Glypican 3 network | 206 | 3 | 0.51 | 5.93 | 0.0145 | 0.0211 | ASD SCZ | |
DB_ID:1604 | Syndecan-4-mediated signaling events | 209 | 3 | 0.51 | 5.84 | 0.0150 | 0.0212 | ASD SCZ | |
DB_ID:178 | Potassium Channels | 76 | 2 | 0.19 | 10.71 | 0.0152 | 0.0213 | EE ASD | |
DB_ID:684 | Asparagine N-linked glycosylation | 77 | 2 | 0.19 | 10.57 | 0.0155 | 0.0215 | - | |
DB_ID:380 | Cyclin E associated events during G1/S transition | 78 | 2 | 0.19 | 10.43 | 0.0159 | 0.0215 | - | |
DB_ID:1656 | AndrogenReceptor | 78 | 2 | 0.19 | 10.43 | 0.0159 | 0.0215 | - | |
DB_ID:1561 | p73 transcription factor network | 78 | 2 | 0.19 | 10.43 | 0.0159 | 0.0215 | - | |
DB_ID:44 | L1CAM interactions | 79 | 2 | 0.19 | 10.30 | 0.0163 | 0.0219 | ASD | |
DB_ID:1493 | Validated targets of C-MYC transcriptional activation | 81 | 2 | 0.20 | 10.05 | 0.0171 | 0.0228 | ASD SCZ | |
DB_ID:439 | Switching of origins to a post-replicative state | 83 | 2 | 0.20 | 9.80 | 0.0179 | 0.0234 | - | |
DB_ID:440 | Orc1 removal from chromatin | 83 | 2 | 0.20 | 9.80 | 0.0179 | 0.0234 | - | |
DB_ID:431 | Removal of licensing factors from origins | 85 | 2 | 0.21 | 9.57 | 0.0187 | 0.0243 | - | |
DB_ID:433 | Regulation of DNA replication | 88 | 2 | 0.22 | 9.25 | 0.0200 | 0.0257 | - | |
DB_ID:383 | Cyclin A:Cdk2-associated events at S phase entry | 90 | 2 | 0.22 | 9.04 | 0.0208 | 0.0265 | - | |
DB_ID:1625 | Notch signaling pathway | 94 | 2 | 0.23 | 8.66 | 0.0226 | 0.0284 | ASD SCZ | |
DB_ID:1457 | Notch-mediated HES/HEY network | 94 | 2 | 0.23 | 8.66 | 0.0226 | 0.0284 | ASD SCZ | |
DB_ID:973 | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | 95 | 2 | 0.23 | 8.57 | 0.0230 | 0.0287 | ASD | |
DB_ID:366 | G2/M Transition | 96 | 2 | 0.24 | 8.48 | 0.0235 | 0.0288 | - | |
DB_ID:943 | SLC-mediated transmembrane transport | 248 | 3 | 0.61 | 4.92 | 0.0235 | 0.0288 | ASD | |
DB_ID:364 | Mitotic G2-G2/M phases | 99 | 2 | 0.24 | 8.22 | 0.0249 | 0.0301 | - | |
DB_ID:93 | Mitotic Prometaphase | 99 | 2 | 0.24 | 8.22 | 0.0249 | 0.0301 | - | |
DB_ID:1476 | Neurotrophic factor-mediated Trk receptor signaling | 101 | 2 | 0.25 | 8.06 | 0.0258 | 0.0309 | - | |
DB_ID:437 | Synthesis of DNA | 109 | 2 | 0.27 | 7.47 | 0.0297 | 0.0353 | - | |
DB_ID:702 | Post-translational protein modification | 114 | 2 | 0.28 | 7.14 | 0.0322 | 0.0380 | - | |
DB_ID:381 | G1/S Transition | 118 | 2 | 0.29 | 6.90 | 0.0343 | 0.0402 | - | |
DB_ID:382 | S Phase | 121 | 2 | 0.30 | 6.72 | 0.0360 | 0.0419 | - | |
DB_ID:1600 | TNF receptor signaling pathway | 299 | 3 | 0.73 | 4.08 | 0.0378 | 0.0436 | ASD | |
DB_ID:1599 | ATM pathway | 307 | 3 | 0.75 | 3.98 | 0.0403 | 0.0462 | SCZ | |
DB_ID:522 | Immune System | 532 | 4 | 1.31 | 3.06 | 0.0426 | 0.0485 | ASD SCZ |